Lexology April 12, 2023
In our January blog post on this topic, The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform, we speculated that in 2023 we could see changes in the regulation of drug pricing in the U.S. It’s only the beginning of April and there have already been some notable developments—albeit in multiple directions.
First, we saw some movement towards greater control over drug prices. On February 9, the Center for Medicare (“CMS”) of the Department of Health and Human Services (“HHS”) released its initial guidance on the implementation of the Inflation Reduction Act (“IRA”) Medicare Prescription Drug Inflation Rebate Program.
Just over a month later, on March 15, 2023, CMS published a list of 27 drugs that will be...
Today's Sponsors
Today's Sponsor